Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference. Karam A, et al. Among authors: katsumata n. Ann Oncol. 2017 Apr 1;28(4):711-717. doi: 10.1093/annonc/mdx011. Ann Oncol. 2017. PMID: 28327917 Free article.
[Gynecologic cancer].
Uehara T, Katsumata N. Uehara T, et al. Among authors: katsumata n. Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94. Gan To Kagaku Ryoho. 2008. PMID: 18799902 Japanese.
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K. Katsumata N, et al. Jpn J Clin Oncol. 2008 Nov;38(11):777-85. doi: 10.1093/jjco/hyn101. Epub 2008 Oct 16. Jpn J Clin Oncol. 2008. PMID: 18927230 Free PMC article. Clinical Trial.
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).
Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, Masuda N, Andoh J, Ikeda T, Shibata T, Takashima S. Katsumata N, et al. Ann Oncol. 2009 Jul;20(7):1210-5. doi: 10.1093/annonc/mdn781. Epub 2009 Mar 2. Ann Oncol. 2009. PMID: 19254942 Free article. Clinical Trial.
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767092 Clinical Trial.
Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
Kumagai S, Sugiyama T, Shoji T, Michimae H, Katsumata N, Aoki D, Terauchi F, Jobo T, Ochiai K, Yasuda M. Kumagai S, et al. Among authors: katsumata n. Int J Gynecol Cancer. 2011 Dec;21(9):1585-91. doi: 10.1097/IGC.0b013e318229266a. Int J Gynecol Cancer. 2011. PMID: 22123713 Clinical Trial.
363 results